Cyclo Therapeutics (NASDAQ:CYTH) Shares Up 3% – Should You Buy?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH)’s share price rose 3% during mid-day trading on Monday . The stock traded as high as $0.73 and last traded at $0.72. Approximately 18,467 shares changed hands during trading, a decline of 73% from the average daily volume of 68,856 shares. The stock had previously closed at $0.70.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CYTH shares. HC Wainwright reissued a “neutral” rating and set a $0.95 target price (down previously from $3.00) on shares of Cyclo Therapeutics in a report on Friday, August 23rd. Maxim Group reissued a “hold” rating on shares of Cyclo Therapeutics in a report on Tuesday, August 27th. Finally, Ascendiant Capital Markets dropped their target price on Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating for the company in a report on Monday, August 26th.

Cyclo Therapeutics Stock Up 3.0 %

The company has a market cap of $20.66 million, a price-to-earnings ratio of -0.80 and a beta of -0.38. The stock has a fifty day moving average price of $0.72 and a two-hundred day moving average price of $1.03.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.